Status:
COMPLETED
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart 70 + biphasic insulin aspart 30 with biphasic human insulin 30 in subjects with ...
Eligibility Criteria
Inclusion
- Subjects with Type 2 diabetes
- Treatment with BHI (biphasic human insulin) 30 twice daily for at least three months
- HbA1c maximum 10.0%
- BMI (Body Mass Index) maximum 35.0 kg/m2
- Able and willing to perform self-blood glucose monitoring (SBGM)
Exclusion
- The receipt of any investigational drug within the last 30 days prior to this trial
- Total daily insulin dose minimum 2.0 U/(kg·day)
- A history of drug abuse or alcohol dependence within the last 5 years
- Impaired hepatic function
- Impaired renal function
- Cardiac disease
- Severe, uncontrolled hypertension
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2002
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01526980
Start Date
May 1 2002
End Date
November 1 2002
Last Update
January 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Newcastle, United Kingdom